- Masimo (NASDAQ:MASI) initiated with Buy rating and $139 (14% upside) price target at Needham citing upside from Philips partnership and its pulse oximeter.
- Rhythm Pharmaceuticals (NASDAQ:RYTM) initiated with Hold rating and $36 (15% upside) price target at Stifel.
- Zogenix (NASDAQ:ZGNX) initiated with Buy rating and $63 (29% upside) price target at BofA/Merrill Lynch. Share up 1% premarket.
- Bovie Medical (NYSEMKT:BVX) initiated with Buy rating and $11 (70% upside) price target at Dougherty & Co.
- UroGen (NASDAQ:URGN) resumed with Buy rating and $70 (57% upside) price target at Stifel.
- Sarepta Therapeutics (NASDAQ:SRPT) resumed with Buy rating and $199 (32% upside) price target at BofA/Merrill Lynch. Shares up 1% premarket.
- Tandem Diabetes Care (NASDAQ:TNDM) downgraded to Neutral at Robert W. Baird. Shares down 4% premarket.